BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 22431577)

  • 1. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
    Zhang SJ; Rampal R; Manshouri T; Patel J; Mensah N; Kayserian A; Hricik T; Heguy A; Hedvat C; Gönen M; Kantarjian H; Levine RL; Abdel-Wahab O; Verstovsek S
    Blood; 2012 May; 119(19):4480-5. PubMed ID: 22431577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
    Liu YC; Illar GM; Bailey NG
    J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
    Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
    Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.
    Li B; Mascarenhas JO; Rampal RK
    Curr Hematol Malig Rep; 2018 Dec; 13(6):588-595. PubMed ID: 30353413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors.
    Je EM; Yoo NJ; Kim YJ; Kim MS; Lee SH
    Int J Cancer; 2013 Jul; 133(1):260-5. PubMed ID: 23280334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.
    Tashakori M; Khoury JD; Routbort MJ; Patel KP; Wang SA; Ok CY; El-Hussein S; Kanagal-Shamanna R; Luthra R; Hu S; Lin P; Pemmaraju N; Bose P; Verstovsek S; Bueso-Ramos CE; Medeiros LJ; Loghavi S
    Mod Pathol; 2022 Nov; 35(11):1677-1683. PubMed ID: 35690645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
    Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
    Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
    Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.
    Patnaik MM; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
    Am J Hematol; 2013 Mar; 88(3):201-6. PubMed ID: 23335386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
    Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
    Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2
    Todisco G; Creignou M; Gallì A; Guglielmelli P; Rumi E; Roncador M; Rizzo E; Nannya Y; Pietra D; Elena C; Bono E; Molteni E; Rosti V; Catricalá S; Sarchi M; Dimitriou M; Ungerstedt J; Vannucchi AM; Hellström-Lindberg E; Ogawa S; Cazzola M; Malcovati L
    Leukemia; 2021 Aug; 35(8):2371-2381. PubMed ID: 33349666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.
    Venton G; Courtier F; Charbonnier A; D'incan E; Saillard C; Mohty B; Mozziconacci MJ; Birnbaum D; Murati A; Vey N; Rey J
    Am J Hematol; 2018 Mar; 93(3):330-338. PubMed ID: 29148089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms.
    Kim T; Ahn JS; Son MH; Novitzky-Basso I; Yi SY; Ahn SY; Jung SH; Yang DH; Lee JJ; Choi SH; Lee JY; Moon JH; Sohn SK; Kim HJ; Zhang Z; Kim DDH
    Leuk Res; 2022 Jul; 118():106858. PubMed ID: 35609360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia.
    Choi HW; Kim HR; Baek HJ; Kook H; Cho D; Shin JH; Suh SP; Ryang DW; Shin MG
    Ann Lab Med; 2015 Jan; 35(1):118-22. PubMed ID: 25553291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.
    Hamilton BK; Visconte V; Jia X; Tabarroki A; Makishima H; Hasrouni E; Abounader D; Kalaycio M; Sekeres MA; Sobecks R; Duong Liu H; Bolwell B; Maciejewski JP; Copelan E; Tiu RV
    Am J Hematol; 2016 Jun; 91(4):406-9. PubMed ID: 26799334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated Phase of Myeloproliferative Neoplasms.
    Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
    Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
    Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
    Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms.
    Mullally A
    Pathologe; 2016 Nov; 37(Suppl 2):175-179. PubMed ID: 27796499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
    Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.